Mid-Cap Comparison: Relay Therapeutics vs. Krystal Biotech
What happened
Relay Therapeutics and Krystal Biotech are both classified as mid-cap healthcare companies. A comparison of the two firms showed that Krystal Biotech has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio, indicating it is currently more affordable than Krystal Biotech.
From tickerreport.com
Why it matters
The comparison highlights differences in financial metrics, including profitability and institutional ownership. Relay Therapeutics has a higher percentage of shares held by institutional investors compared to Krystal Biotech.
From tickerreport.com
Who's involved
- Relay TherapeuticsMid-cap healthcare company subject to financial comparison
- Krystal Biotech, Inc.Mid-cap biotechnology company subject to financial comparison
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Krystal Biotech, Inc.Speculative
Its higher revenue and earnings could impact its competitive position in the market.
Keep exploring
The entities involved
-
Relay Therapeutics
company in Cambridge, United States
Nothing else this week.
-
Krystal Biotech, Inc.
biotechnology company
Nothing else this week.